Dr. Reddy's Laboratories
) recently announced the launch of its generic version of
) Amoxil (amoxicillin) tablets, capsules, and oral suspension in
the US following the receipt of Food and Drug Administration (FDA)
approval for its Abbreviated New Drug Application (ANDA).
Dr. Reddy's launched its generic version of Amoxil tablets (500
mg and 875 mg), capsules (250 mg and 500 mg) and oral suspension
(125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) in the US
on September 17, 2012.
Amoxil is marketed for the treatment of bacterial infection of
the ear, nose, throat, genitourinary tract, skin and skin
structure, and lower respiratory tract.
According to IMS Health, US branded and generic sales of Amoxil
tablets (875 mg), capsules and oral suspension were approximately
$22.2 million, $67.2 million and $89.5 million, respectively, for
the twelve months ended June 30, 2012.
We note Dr. Reddy's had quite a few generic launches this year.
On September 11, 2012, it launched its generic version of
) hypertension drug Toprol XL (metoprolol succinate extended
release) - tablets (25 mg, 50 mg, 100 mg and 200 mg) in the US.
Dr. Reddy's also launched a generic version of
Merck & Co.
) blockbuster asthma and allergy drug Singulair and
) blockbuster cholesterol drug, Lipitor. Other recent launches
include Dr. Reddy's generic version of
Roche Holdings Ltd.
) Boniva, Glaxo's Requip and
) over-the-counter (OTC) drug, Prevacid.
Currently, we have a Neutral recommendation on Dr. Reddy's. The
stock carries a Zacks #3 Rank (short-term Hold rating).
ASTRAZENECA PLC (AZN): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
DOCTOR REDDYS (RDY): Free Stock Analysis Report
(RHHBY): ETF Research Reports
To read this article on Zacks.com click here.